Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like monoclonal antibodies, therapeutic molecules, small molecules, and fluids, improving dispersion and absorption. Key products include Hylenex recombinant for enhancing subcutaneous drug delivery in medical imaging and XYOSTED for testosterone replacement therapy via auto-injector. The ENHANZE drug delivery technology is licensed to partners for co-formulation in treatments targeting oncology, endocrinology, and other areas, with recent approvals for products like RYBREVANT FASPRO, DARZALEX Faspro, and collaborations such as with Takeda for vedolizumab. Halozyme Therapeutics Inc. also expanded its portfolio through the acquisition of Elektrofi, adding high-concentration biologic formulations via Hypercon technology. Operating primarily in the United States with international reach, the company supports biopharmaceutical partners in creating patient-friendly therapies that enhance convenience, tolerability, and adherence. Founded in 1998 and headquartered in San Diego, California, Halozyme Therapeutics Inc. plays a vital role in advancing drug delivery innovations across therapeutic segments.